Explore all of ul.com

The US Food and Drug Administration has drafted a guidance document on gluten labeling in drug products.

This draft guidance intends to convey to drug manufacturers FDA’s recommendations on how certain oral drug products should be labeled regarding gluten, a matter of interest to individuals with celiac disease.

The draft is open for comments until February 12, 2018.

SOURCE

Share

Subscribe to Newsletter

The CRS monthly Newsletter focuses on the latest initiatives, insights and information for manufacturers and retailers across industries.